Ican Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 02-06-2024
- Paid Up Capital ₹ 0.10 M
as on 02-06-2024
- Company Age 12 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
About Ican Pharma
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Arup Chatterjee, Bholanath Saha, and Swapna Chatterjee serve as directors at the Company.
- CIN/LLPIN
U24100WB2012PTC175931
- Company No.
175931
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Mar 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
South 24 Parganas, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Ican Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arup Chatterjee  | Additional Director | 20-Jun-2023 | Current |
| Bholanath Saha | Director | 01-Nov-2021 | Current |
| Swapna Chatterjee | Director | 01-Nov-2021 | Current |
Financial Performance of Ican Pharma.
Ican Pharma Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Ican Pharma?
In 2017, Ican Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ican Paints Private LimitedActive 12 years 10 monthsArup Chatterjee, Bholanath Saha and 1 more are mutual person
- Ican Adhesive Private LimitedActive 12 years 10 months
Arup Chatterjee, Bholanath Saha and 1 more are mutual person
- Ican Coating Private LimitedActive 12 years 9 months
Arup Chatterjee, Bholanath Saha and 1 more are mutual person
- Ican Marine Private LimitedActive 12 years 8 months
Arup Chatterjee, Bholanath Saha and 1 more are mutual person
- Ican Ink Private LimitedActive 12 years 7 months
Arup Chatterjee, Bholanath Saha and 1 more are mutual person
- Ican Materials Private LimitedActive 12 years 7 months
Arup Chatterjee, Bholanath Saha and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ican Pharma?
Unlock and access historical data on people associated with Ican Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ican Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ican Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
